1 citations
,
November 2024 in “Expert Opinion on Drug Safety” In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.
2 citations
,
May 2025 in “Frontiers in Pharmacology” In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.
50 citations
,
December 2006 in “Bone” This study found that the steroidal aromatase inhibitor exemestane stimulated proliferation of human osteoblast cells, suggesting both androgen receptor-dependent and independent pathways are involved.
May 2013 in “UTUPub (University of Turku)” This study suggests that adding androgens to menopausal hormone therapy may reduce breast cancer risk by counteracting estrogen-driven proliferation in postmenopausal breast tissue.
7 citations
,
September 2023 in “Cancer Treatment Reviews” This review highlights the possible impact of side effects from endocrine therapy on quality of life, emphasizing that these can lead to poor adherence and early treatment discontinuation in patients with hormone receptor positive early breast cancer, potentially worsening survival outcomes.